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Objective/background: Myelodysplastic syndromes (MDSs) are a group of monoclonal
hematopoietic diseases consisting of a number of various entities. The presence of differences
in chromosomal content of cells within the same individual is known as chromosomal mosai-
cism. The impact of mosaic pattern on the prognosis of MDS has been unclear. In this study,
we aimed to determine the impact of mosaic pattern on the survival of patients with MDS.
Methods: We retrospectively evaluated 119 patients diagnosed with MDS at the Trakya Univer-
sity Faculty of Medicine, Department of Hematology. Giemsa–Trypsin–Giemsa banding was
used to evaluate chromosomal abnormality.
The effect of chromosomal abnormality mosaicism on overall survival and transformation to
acute leukemia was evaluated by Kaplan–Meier survival analysis.
Results: The mean age at diagnosis was 66.3 years, and the mean disease duration was
24.2 months. Chromosomal abnormality was observed in 32.5% of patients. Patients with chro-
mosomal abnormalities comprising at least 50% metaphases had significantly lower overall sur-
vival than patients with abnormality comprising up to 50% of all abnormal metaphases
(p = .003). There were no differences in transformation to acute leukemia among patients with
higher and lower chromosomal mosaicism (p = .056).
42 M.S. Uyanik et al.Conclusion: The most important outcome of this study was to demonstrate worse overall sur-
vival rates in MDS patients with higher abnormal chromosomal mosaicism than patients with
lesser abnormal chromosomal mosaicism. Higher levels of abnormal chromosomal mosaicism
did not predict transformation to acute leukemia. The cause of worse outcomes of patients
with higher abnormal chromosomal mosaicism may be related to clonal mass.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Background
Myelodysplastic syndromes (MDSs) are a group of mono-
clonal hematopoietic diseases consisting of a number of var-
ious entities [1]. Certain artificial taxonomies and
Prognostic Scoring Systems have emerged to overcome this
heterogeneity and nonuniformity [2,3]. The World Health
Organization’s (WHO) classification of myeloid neoplasms
and acute leukemia [4] and the International Prognostic
Scoring System (IPSS) [5] have become standard tools for
MDS classification and risk stratification. Bone marrow blast
percentage, chromosomal abnormalities, and the number of
cytopenias are used as markers to predict prognosis within
the IPSS [5]. The IPSS was not intended to be used after ini-
tial diagnosis, and therefore, the WHO-based Prognostic
Scoring System (WPSS) was developed for use as a dynamic
scoring system [2,6]. Blast count, depth of peripheral
cytopenias, chromosomal abnormalities, WHO subtype,
and transfusion dependency are markers typically used in
universal scoring systems [6–8]. Besides these well-known
markers, additional markers such as serum lactate dehydro-
genase, performance status, ferritin, albumin, b2-
microglobulin, and bone marrow fibrosis are prognostic
markers, which make independent contributions to the
prognosis of MDS [3,5,6,9].
Chromosomal abnormalities are observed in approxi-
mately 40% of patients with MDS [7,10]. Genome-wide asso-
ciation studies typically show approximately 74%
chromosomal abnormality in patients with MDS [11]. MDS
is a clonal process caused by the accumulation of cellular
maturation defects and chromosomal abnormalities [12].
Serial genetic abnormality inside the pluripotent stem cell
gives rise to the abnormal proliferation of hematopoietic
cells [13]. Accumulation of immature cells in bone marrow
disrupts normal hematopoiesis that demonstrates the
importance of clonal mass in MDS. It is well-known that
MDS patients with certain chromosomal abnormalities, such
as chromosome 7 abnormalities and complex karyotypes,
experience worse clinical outcomes than patients with nor-
mal karyotypes [14]. The impact of clonal mass on the prog-
nosis of malignancy has been demonstrated in solid organ
malignancies as well as in MDS [15]. Different study groups
have demonstrated the impact of the number of complex
karyotypes on the prognosis of MDS, showing the effect of
clonal mass on prognosis [7,14].
The presence of differences in chromosomal content of
cells within the same individual is known as ‘‘chromosomalmosaicism” [16]. The association between chromosomal
mosaicism and dermatological diseases [17], gynecological
abnormalities [18,19], cognitive disorders [20,21], solid
malignancies [22], and recently, hematological malignan-
cies has already been demonstrated [15]. By contrast, the
impact of mosaic pattern on the prognosis of MDS remains
unclear. It was recently demonstrated that MDS patients
with a mosaic of normal and abnormal metaphases had
better survival rates than patients with only abnormal meta-
phases [7]. These findings may be taken into account in
terms of the impact of clonality on the prognosis of MDS.
In this study, we aimed to determine the impact of the
degree of mosaic pattern, one of the signs of clonal mass,
on the survival of MDS.Materials and methods
We evaluated 119 MDS patients at Trakya University
Faculty of Medicine Department of Hematology between
January 2010 and June 2014. Diagnosis of 88 patients
were established at this time period. Cytopenia
cutoff for absolute neutrophil counts was set at 1500/lL;
10 g/dL for hemoglobin; and 100,000/lL for platelets.
Bone marrow aspiration and biopsies were performed for
all patients. Bone marrow biopsies were evaluated by an
experienced hematopathologist (F.O.P.). Dysplasia cutoff
was defined as 10% for each serial. All karyotyping was
performed from bone marrow samples. Patients diagnosed
with chronic myelomonocytic leukemia, juvenile
myelomonocytic leukemia, and atypical chronic myeloid
leukemia were excluded from the study. The local ethical
committee approved this study.
Giemsa–Trypsin–Giemsa/Giemsa–Trypsin–Leishman
banding was used for karyotyping. As a rule, four bands from
chromosomes 13–18 should be observed for a sample.
Patients with a minimum of 400 bands were included in this
study. The type of chromosomal abnormality (qualitative
and/or quantitative) was recorded, and the metaphase
count of the abnormality was also noted. The International
System for Human Cytogenetic Nomenclature—1995 criteria
were used to define abnormal clonality of chromosomes.
Three groups of patients were observed: (a) patients with
no chromosomal abnormality; (b) patients with a mosaic
of normal and abnormal metaphases (abnormal chromoso-
mal count < 50% of all abnormal metaphases); and (c)
patients with a mosaic of normal and abnormal metaphases
(abnormal chromosomal countP 50% of all abnormal meta-
phases) or bearing only abnormal chromosomes.
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SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA) was
used for data analysis. Differences between continuous vari-
ables were evaluated using Student t test, and differences
between categorical variables were evaluated using
Chi-square test. Kaplan–Meier survival curves were used
to define overall survival and progression to acute myeloid
leukemia (AML). The effects of certain variables on overall
survival were analyzed using Cox regression models with
time-dependent covariates. Differences between patient
groups were analyzed by log-rank test. Statistical signifi-
cance was p < .05.Table 1 Sociodemographic findings of myelodysplastic syndrome
FAB
RA
RARS
RAEB
RAEB-t
Total
WHO
RAUC
RCMD
RARS
RAEB-I
RAEB-II
Total
WPSS
Very low
Low
Intermediate
High
Very high
IPSS
Low
Intermediate-1
Intermediate-2
High
Treatment
No medication
Palliative therapy
ESAs
Thalidomide
HMAs
Eltrombopag
Chemotherapy
Transfusion dependency
Transfusion dependent
Rarely transfused
Iron chelation
ESAs = erythroid stimulating agents; FAB = French–American–British;
Scoring System; RA = refractory anemia; RAEB = refractory anemia with
RAEB-t = refractory anemia with excessed blast-transformation; RAUC =
cytopenia with multilineage dysplasia; WHO = World Health OrganizatEthical standards
The authors assert that all procedures contributing to this
work comply with the ethical standards of the relevant
national and institutional committees on human experimen-
tation and with the Helsinki Declaration of 1975, as revised
in 2008.
Results
The mean age at diagnosis was 66.3 ± 12.3 years
(27–91 years). The median age was 69 years. The meanpatients.
N %
93 78.2
1 0.8
18 15.1
2 17
114 95.8
21 17.4
73 61.3
1 0.9
8 6.7
11 9.2
114 95.8
17 14.3
29 24.4
20 16.8
20 16.8
4 3.4
27 22.7
43 36.1
17 14.3
4 3.4
40 33.2
39 32.7
5 4.2
1 0.8
7 5.9
1 0.8
7 5.9
23 19.3
16 13.4
7 6
HMAs = hypo-methylating agents; IPSS = International Prognostic
excessed blast; RARS = refractory anemia with ringed sideroblast;
refractory cytopenia with unilineage dysplasia; RCMD = refractory
ion; WPSS = WHO Prognostic Scoring System.
44 M.S. Uyanik et al.disease duration was 24.2 ± 24.8 months (3–132 months). In
this study, 50.4% of patients were women and 49.6% were
men. Regarding therapy-related MDS, two patients had his-
tory of malignancies. One patient had been treated with
chemotherapy (0.8%) for Hodgkin’s lymphoma, and the
other had been treated with radiotherapy (0.8%) for breast
carcinoma. Distribution of the patients according to the Fr
ench–American–British and WHO classifications, and distri-
bution of patients according to the IPSS and WPSS risk scor-
ing systems are presented in Table 1. According to the WHO
classification, most of the patients (61.3%) were in the
refractory cytopenia with multilineage dysplasia (RCMD)
group. According to the IPSS risk scoring system, 60 patients
(50.4%) were distributed in the Intermediate 1 and Interme-
diate 2 groups.
Treatment and transfusion policy and dependency are
also shown in Table 1. Transfusion dependency was
observed in 23 (19.3%) patients. Transfusion was rarely used
in palliative care for 16 (13.4%) patients. Iron chelation was
used in seven (6%) patients and the mean chelation durationFigure 1 (A) Overall survival according to the World Health O
myeloid leukemia (AML) according to the WHO classification. (C) O
System (IPSS) classification. (D) Transformation to AML according twas 17.6 ± 16.4 months. During the follow-up period, AML
developed in 11 (9.3%) patients. A total of 16 (13.4%)
patients died, and 14 (11.8%) patients were lost to follow
up.
Patients’ overall survival and transformation to AML
according to the WHO classification are demonstrated in
Figure 1A and B. Overall survival of groups significantly dif-
fered according to the WHO classification (p = .001). There
was no overall survival difference between the refractory
anemia with ringed sideroblasts and refractory cytopenia
with unilineage dysplasia (RCUD) groups. Overall survival
of RCUD was significantly longer than refractory anemia
with excess blasts-I (RAEB-I; p = .008) and RAEB-II
(p = .004). RCMD patients significantly lived longer than
patients with RAEB-I (p = .01). There was no overall survival
difference between RCMD and RAEB-II patients according to
the WHO classification. Transformation to AML was signifi-
cantly different between groups (p < .0001). AML transfor-
mation was significantly lower in the RCUD group than in
the RAEB-I (p = .008) and RAEB-II (p = .001) groups. Patientsrganization (WHO) classification. (B) Transformation to acute
verall survival according to the International Prognostic Scoring
o the IPSS classification.
Figure 2 Impact of abnormal clonal mosaicism on overall
survival.
Chromosomal mosaicism in myelodysplastic syndrome 45with RCMD were significantly transformed to AML later than
the RAEB-I (p = .001) and RAEB-II (p < .0001) groups. The
IPSS was also used to demonstrate the differences in overall
survival and transformation to AML between groups (Fig-
ure 1C and D). Overall survival and transformation to AML
were significantly different according to the IPSS
(p < .0001).
Chromosomal abnormality was observed in 32.5% of the
patients. Chromosomal abnormality frequency and the
mean values of abnormal metaphase counts are shown in
Tables 2 and 3, respectively. We further divided chromoso-
mal abnormalities into two groups: (a) abnormalities com-
prising up to 50% of all abnormal metaphases, and (b)
abnormalities comprising at least 50% of all metaphases.
Patients in whom chromosomal abnormality comprised at
least 50% metaphases significantly had lower overall survival
than patients in whom abnormality comprised utmost 50% of
all abnormal metaphases (p = .003; Figure 2). Eight of the 80
patients (9.1%) in whom abnormalities comprised up to 50%
of all abnormal metaphases transformed to AML. Three ofTable 2 Chromosomal abnormality distribution.
Quantitative abnormalities (%)
Monosomy in 2 different chromosomes 4.8
Monosomy 20 3.6
Monosomy 19 2.4
Monosomy 22 2.4
Monosomy 17 1.2
Monosomy 18 1.2
Monosomy 21 1.2
Monosomy Y 1.2
Trisomy 8 1.2
Hypodiploidy 39
Hyperdiploidy 3
Hypo-tetra diploidy 4
Tetradiploidy 4
Qualitative abnormalities
Complex karyotypea 8.4
Del 15q 8.4
inv (9)(11q13) 1.2
t(3;8) 1.2
a Complex karyotype was defined as the presence of three or
more unassociated structural abnormalities (International Prog-
nostic Scoring System).
Table 3 Counts of abnormal metaphases.
Abnormality type Mean metaphase count (min–max)
Monosomy 2 0.80 ± 0.20 (0–20)
Monosomy 7 0.04 ± 0.20 (0–1)
Monosomy 11 0.04 ± 0.20 (0–1)
Monosomy 14 0.16 ± 0.67 (0–3)
Monosomy 15 0.14 ± 0.64 (0–3)
Monosomy 17 0.26 ± 0.91 (0–4)
Monosomy 18 0.40 ± 1.26 (0–4)
Monosomy 19 0.27 ± 0.92 (0–4)nine patients (25%) with abnormalities comprising at least
50% of all metaphases transformed to AML. There was no
difference in transformation to AML among patients with
higher and lower chromosomal mosaicism (p = .056).
The following were chosen as covariates for multivariate
analysis: presence of 50% or more abnormal metaphases of
chromosomal mosaicism, age, transfusion dependency, dis-
ease duration, and blast count demonstrated by flow cytom-
etry. In multivariable analysis, chromosomal mosaicism
(hazard ratio [HR] = 0.476, 95% confidence interval [CI],
0.264–0.859, p = .014), transfusion dependency
(HR = 8.496, 95% CI, 1.3226–54.394, p = .024), disease dura-
tion (HR = 0.872, 95% CI, 0.771–0.986, p = .029), and blast
count (HR = 1.085, 95% CI, 1.025–1.150, p = .005) have been
shown to affect overall survival.
Discussion
The most important outcome of this study was demonstrat-
ing shorter overall survival in MDS patients with larger clonal
mass than patients with smaller clonal mass by implement-
ing chromosomal mosaicism. Haase et al. [7] recently
showed longer median survival for patients with mosaic pat-
tern than patients harboring solely abnormal metaphases.
However, researchers of that study did not determine any
cutoff value for mosaic pattern. In this study, we evaluatedAbnormality type Mean metaphase count (min–max)
Monosomy 20 0.21 ± 0.91 (0–4)
Monosomy 21 0.25 ± 0.94 (0–4)
Monosomy Y 0.28 ± 1.3 (0–9)
Trisomy 8 0.16 ± 0.17 (0–1)
Inv9 0.31 ± 2.0 (0–13)
11q23 0.21 ± 1.02 (0–5)
Del15q 0.03 ± 0.24 (0–2)
46 M.S. Uyanik et al.clonal mass based on the impact of chromosomal mosaic
pattern and divided chromosomal abnormalities into two
groups, namely, (a) abnormalities that comprised up to
50% of all abnormal metaphases and (b) abnormalities that
comprised at least 50% of all metaphases.
Recently, it has been demonstrated that hematological
cancers were 5.4 times higher in healthy individuals with
chromosomal mosaicism than in controls with normal kary-
otype [15]. Furthermore, up to 35 times higher risk of acute
leukemia progression was observed in healthy individuals
with chromosomal mosaicism than their counterparts [23].
In our study, there was no difference in transformation to
AML between patients based on chromosomal mosaicism.
In a study by Schick et al. [15], MDS developed in only six
of 229 individuals with chromosomal mosaicism. Research-
ers emphasized that the strongest association was between
abnormal chromosomal mosaicism and leukemia. In
comparison to this, the association between chromosomal
mosaicism and other hematological malignancies was
weaker [15]. These studies were performed on healthy indi-
viduals with chromosomal mosaicism to predict hematolog-
ical malignancies, whereas in our study, we used
chromosomal mosaicism to predict AML transformation in
MDS patients. Another reason for this inconsistency between
our study and recently published data may be due to the
methods used to demonstrate mosaicism.
The effect of normal residual metaphases was evaluated
in patients with AML in a couple of studies [14,24,25]. In a
study by Xie et al. [24], the influence of residual normalmeta-
phases in AML patients with monosomal karyotype was stud-
ied, and a higher percentage of normalmetaphaseswas found
to be associated with longer survival in the univariate/
multivariate model. These results indicate that even in
well-defined cytogenetic groups, such as monosomal kary-
otype, chromosomal mosaicism could cause heterogeneity.
The study population of Estey et al. [14] was composed of
AML/high-risk MDS patients with chromosome 5 and/or 7
abnormalities, treated with conventional chemotherapy.
One of the characteristics that Estey et al. [14] demonstrated
to find out the relatively longer surviving patients was the
presence or absence of more than one normal karyotype.
They found that patientswith normal karyotypewith chromo-
some 5 and/or 7 abnormalities had a better survival rate than
patients with no accompanying normal karyotype [14].
Beyond this finding, 10% of the patients bearing chromosome
5 and/or 7 abnormalities with normal karyotype had essen-
tially identical outcomes to patients with a normal karyotype
treated in the same facility at the same period [14].
The reason for the adverse effect of higher abnormal
chromosome mosaicism in MDS is unclear. In a study by
Medeiros et al. [26] higher normal karyotype mosaicism
was associated with worse outcomes among core-binding
factor-AML patients. The hypothesis used by the authors
to explain the worse outcome was proposed as ‘‘blasts with
normal karyotype were more resistant to conventional
chemotherapy than blasts with core-binding factor kary-
otype.” Similarly, patients with chromosome 5 and/or 7
abnormalities and normal karyotype mosaicism were associ-
ated with better outcome [14]. Although we are able to
demonstrate worse outcomes in patients with higher abnor-
mal chromosomal mosaicism, the effect of chromosomal
mosaicism should differ in patients having very goodkaryotypes such as monosomy Y and del (11q) or poor or
very poor karyotypes according to the information
presented in these two studies. Our hypothesis is that the
reason for worse outcome of patients with higher abnormal
chromosomal mosaicism may be the association between
higher clonal mass and higher abnormal chromosome count.
Further studies on the effect of chromosomal mosaicism on
disease prognosis within different risk groups would be help-
ful to elucidate the effect of mosaicism in MDS.
The limitations of our study were (a) its cross-sectional
nature, (b) small sample size, (c) not using fluorescence
in situ hybridization (FISH) next to Giemsa–Trypsin–Giemsa
banding, (d) relatively small follow-up time, and (e) only
one hematopathologist evaluated the tissue samples. Typi-
cally, G-banded chromosomal analysis and FISH are the
two most useful techniques to identify chromosomal mosai-
cism. We used G-banded chromosomal analysis, a relatively
low-resolution technique, to evaluate chromosomal
abnormality. It is known that aberrations can be detected
by G-banded karyotyping at a resolution 5–10 megabases.
FISH enables visualization of targeted chromosomal regions
at a resolution greater than 150 kilobases within a specific
genetic locus. Karyotyping and FISH have been commonly
used in tandem to overcome the limitation of FISH to detect
only specific regions in clinical practice. One of the major
weaknesses of our study was that only one hematopatholo-
gist evaluated the bone marrow samples. It would be ideal
to report concordance rates among the hematopathologists,
to increase the value of the study. Further studies with two
or more techniques to evaluate the mosaic patterns of chro-
mosomal abnormality would be appropriate to demonstrate
the impact of mosaic pattern on survival for MDS patients.
In conclusion, higher abnormal chromosomal mosaicism
is associated with worse overall survival in MDS patients
with chromosomal abnormality. Chromosomal mosaicism
was not shown to have an impact on transformation to
AML in MDS patients. The reason for the worse outcomes
observed for abnormal chromosomal mosaicism may be
related to higher clonal mass.Conflicts of interest
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